Infiltrating bladder urothelial carcinoma

This study tests whether adding immunotherapy drugs (nivolumab, with or without BMS-986205) to standard chemotherapy before and after bladder cancer surgery helps more people achieve a complete response and live longer without the cancer returning. About 855 adults with muscle-in…

This Phase 2 trial tests whether adding visugromab to the immunotherapy nivolumab helps shrink muscle-invasive bladder cancer before surgery. The study includes 31 patients who cannot take or refuse standard cisplatin chemotherapy. The main goal is to see how many patients have n…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before and after bladder removal surgery helps people with muscle-invasive bladder cancer live longer without the cancer coming back. About 900 participants took part. The goal was to s…

This phase 2 trial tests an experimental drug called LDP, an anti-PD-L1 monoclonal antibody that helps the immune system attack cancer cells. It enrolls adults with muscle-invasive bladder cancer, non-clear cell kidney cancer, or advanced penile cancer. Participants receive LDP i…

This phase 2 trial tested a combination of two drugs—TAR-200 (placed directly into the bladder) and cetrelimab (an immunotherapy given by IV)—in 163 people with muscle-invasive bladder cancer who were scheduled for bladder removal surgery and could not or would not take standard …

This pilot study tested whether adding the anti-inflammatory drug celecoxib (Celebrex) to standard chemotherapy before bladder cancer surgery is safe and affects tumor genes. 22 people with muscle-invasive bladder cancer took part. The goal was to see how the treatment changed ca…

This study tested a new way to treat muscle-invasive bladder cancer by tailoring therapy based on each patient's tumor genetics. After initial chemotherapy, patients with a good response could avoid bladder removal and instead opt for active monitoring or less invasive treatments…

This phase 2 trial tested a new cancer vaccine (IO102-IO103) combined with the immunotherapy drug pembrolizumab as a first treatment for people with advanced lung, head/neck, or bladder cancer that had spread. The study enrolled 63 participants to see if the combination is safe a…

This study tested a drug called sacituzumab govitecan given before bladder removal surgery in 44 people with muscle-invasive bladder cancer who could not take or refused standard cisplatin chemotherapy. The goal was to see if the drug could completely eliminate the tumor by the t…

This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (gemcitabine and cisplatin) could shrink tumors more effectively before bladder cancer surgery. 39 people with muscle-invasive bladder cancer received the combination before …

This phase 2 trial tested a combination of two chemotherapy drugs, cabazitaxel and cisplatin, given before surgery to remove the bladder in 28 patients with invasive bladder cancer. The goal was to see if the drugs could shrink the tumor enough to improve outcomes. The study also…

This early-stage study tested a combination of two drugs—CG0070 (a virus that targets cancer cells) and nivolumab (an immunotherapy that boosts the immune system)—in 21 people with muscle-invasive bladder cancer who were not eligible for standard chemotherapy. The goal was to see…

This completed study tested a three-step treatment for muscle invasive bladder cancer: chemotherapy, then a minimally invasive surgery to remove the tumor, followed by radiation. The goal was to treat the cancer while keeping the bladder intact, which could improve quality of lif…

This study tested a weekly, higher-dose radiation schedule (hypofractionated radiotherapy) for people with muscle-invasive bladder cancer who cannot have standard daily radiation or surgery. It included 65 participants and compared standard radiation planning with a newer 'adapti…

This study tested a combination of two drugs (toripalimab and gemcitabine) given before surgery to 50 people with muscle-invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. The goal was to see how many patients had their tumors shrink or disappear. T…

This pilot study tested whether giving pembrolizumab (an immunotherapy) along with standard chemotherapy before surgery could help people with rare types of muscle-invasive bladder cancer. 17 participants received the combination, and researchers measured how many had no cancer l…

This pilot study tested whether a new radioactive tracer called 18F-fluciclovine, used with a PET/CT scan, can better determine the extent of muscle invasive bladder cancer before surgery. Sixteen participants with bladder cancer received the tracer and scan before their planned …

This study tested how well a special MRI scan (called multiparametric MRI) can tell if bladder cancer has grown into the muscle layer of the bladder. Researchers used a scoring system called VI-RADS to interpret the scans. The study included 60 people with bladder masses who were…

This study tested whether a special type of PET/MR scan (using radioactive water) can accurately tell if bladder cancer has been completely eliminated by chemotherapy. 13 patients with muscle-invasive bladder cancer were scanned before and after chemotherapy, and the results were…

This study looked at whether measuring bits of tumor DNA in blood and urine (called ctDNA) is possible in people with muscle-invasive bladder cancer receiving a combination of surgery, radiation, and chemotherapy. The goal was to see if this approach could help monitor how well t…

This study looked at whether FDG-PET CT scans can more accurately stage muscle invasive bladder cancer compared to standard CT scans. Researchers reviewed records of 130 patients who had PET CT scans at diagnosis. The goal was to see if PET CT better detects cancer spread to lymp…